Big pharma covets generics' access to new markets, analysts say
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo's pending acquisition of Ranbaxydemonstrates that big pharmaceutical companies are looking at buying generic drug makers to access high-growth markets, not because of their unbranded business, Wall Street experts told the Generic Pharmaceutical Association's recent annual policy meeting.